Li B, Ye J J
Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Zhonghua Yan Ke Za Zhi. 2018 Aug 11;54(8):625-630. doi: 10.3760/cma.j.issn.0412-4081.2018.08.014.
Diabetic macular edema (DME) is the leading cause of vision loss in diabetics. The destruction of blood retinal barrier is the primary pathological feature. At present, a large number of animal experiments and clinical studies show that DME not only has abnormal vascular structure, but also is an inflammatory disease. A variety of inflammatory media and chemokine are involved in the process of DME. With the extensive clinical application of anti-vascular endothelial growth factor (VEGF), the treatment of DME got a revolutionary breakthrough. However, unlike proliferative diabetic retinopathy (PDR), DME patients response intensively to anti-VEGF agents and couldn't resolve completely despite of multiple injections. Therefore, in addition to VEGF, other possible therapeutic targets and clinical trials of new drugs are also widely carried out. This article reviews the therapeutic process of DME. .
糖尿病性黄斑水肿（DME）是糖尿病患者视力丧失的主要原因。血视网膜屏障的破坏是其主要病理特征。目前，大量动物实验和临床研究表明，DME不仅存在血管结构异常，而且是一种炎症性疾病。多种炎症介质和趋化因子参与了DME的发病过程。随着抗血管内皮生长因子（VEGF）在临床上的广泛应用，DME的治疗取得了革命性突破。然而，与增殖性糖尿病视网膜病变（PDR）不同，DME患者对抗VEGF药物反应强烈，尽管多次注射仍无法完全治愈。因此，除VEGF外，其他可能的治疗靶点和新药临床试验也在广泛开展。本文综述了DME的治疗进展。
